Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

7 Aug 2020 14:20

RNS Number : 5433V
ValiRx PLC
07 August 2020
 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Director Dealing

 

London, UK 7 August 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces the following dealing in the ordinary shares of the Company made by a Director.

 

On 7 August 2020, the Company was informed that Dr Kevin Cox, Non-executive Chairman of the Company, acquired 117,000 ValiRx ordinary shares at an average price of 8.2 pence per share on 7 August 2020, representing approximately 0.22% of the Company's issued ordinary share capital. Following this acquisition, Dr Cox now holds an interest in 250,333 ValiRx ordinary shares, representing approximately 0.46% of the Company's issued ordinary share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information please contact:

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

 

Cairn Financial Advisers LLP(Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 0880

 

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

 

Tel: +44 (0) 20 7469 0930

 

 

 

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Kevin Cox

2

Reason for notification

a.

Position/Status

Non-executive Chairman

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

 

213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary Shares

 

 

ISIN: GB00BLH13C52

b.

Nature of the transaction

On market Purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

8.2 pence

 

117,000

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

07/08/2020

f.

Place of the transaction

London, UK

 

         

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBXGDIIBGDGGR
Date   Source Headline
23rd Jul 20194:02 pmRNSHolding(s) in Company
23rd Jul 20197:00 amRNSAppointment of Joint Broker
10th Jul 20197:00 amRNSMarketing and Communications Update
9th Jul 201911:14 amRNSChange of Registered Address
4th Jul 20197:00 amRNSUpdate re VAL301
28th Jun 20191:33 pmRNSHolding(s) in Company
28th Jun 201912:31 pmRNSIssue of Equity
28th Jun 201912:03 pmRNSResult of AGM
26th Jun 201912:00 pmRNSHolding(s) in Company
26th Jun 20197:00 amRNSUS Notice of Allowance-VAL201 & Metastatic Cancer
25th Jun 20192:50 pmRNSFurther re: Termination of Subscription Agreement
24th Jun 201912:45 pmRNSHolding(s) in Company
21st Jun 201912:00 pmRNSHolding(s) in Company
20th Jun 20197:00 amRNSUpdate on VAL201 Clinical Trial
19th Jun 201912:00 pmRNSHolding(s) in Company
13th Jun 20197:00 amRNSPlacing, Subscription Agreement & Issue of Warrant
10th Jun 20197:00 amRNSSubscription Agreement Update
5th Jun 20197:00 amRNSNotice of AGM & Update of Subscription Agreement
31st May 201911:07 amRNSSubscription Agreement Update
31st May 201910:42 amRNSHolding(s) in Company
30th May 201910:30 amRNSHolding(s) in Company
29th May 201911:44 amRNSHolding(s) in Company
29th May 20197:00 amRNSFinal Results
28th May 20197:00 amRNSSubscription Agreement Update
23rd May 201912:02 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription Agreement Update
13th May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSAcquisition of Intellectual Property& JV Agreement
29th Apr 20192:06 pmRNSSecond Price Monitoring Extn
29th Apr 20192:01 pmRNSPrice Monitoring Extension
29th Apr 201911:07 amRNSSecond Price Monitoring Extn
29th Apr 201911:01 amRNSPrice Monitoring Extension
29th Apr 201910:55 amRNSHolding(s) in Company
26th Apr 20197:00 amRNSSubscription, Convertible Funds and Warrant Issue
15th Apr 20197:15 amEQSHardman & Co Research: Valirx (VAL): VAL401 is going forward
26th Mar 20197:00 amRNSValiSeek Update
21st Mar 20197:00 amRNSUpdate on VAL201 & VAL301 Development Progress
21st Feb 201911:22 amRNSPlacing, Issue of Equity and Warrant
31st Jan 20197:00 amRNSNew patent grant allowances for VAL301
11th Jan 20197:00 amRNSPublication of VAL401 peer-reviewed article
9th Jan 201910:41 amRNSValiRx endorses the Government's new NHS strategy
3rd Jan 20197:00 amRNSHolding(s) in Company
18th Dec 20184:41 pmRNSSecond Price Monitoring Extn
18th Dec 20184:36 pmRNSPrice Monitoring Extension
18th Dec 201811:25 amRNSIssue of Equity / PDMR Shareholdings
18th Dec 20187:00 amRNSUpdate on VAL401 - Peer-review Acceptance
10th Dec 20187:00 amRNSUpdate on VAL201 Clinical Trial
5th Nov 20187:00 amRNSRe scientific and investor meetings
1st Nov 20187:15 amEQSHardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed
24th Oct 20187:00 amRNSAlign Research Initiates Coverage

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.